A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B ...

People who are colorblind may be missing a life-saving warning sign of bladder cancer. Analysis of the electronic health ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.

The American Cancer Society estimates that over 80,000 individuals will be diagnosed with bladder cancer this year.

ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

The Saudi Food and Drug Authority (SFDA) has granted conditional approval for Anktiva, a groundbreaking cancer therapy, for ...

With an estimated 12,600 new cases of bladder cancer in Canada in 2025, plus almost 84,870 in the United States, ranking 5th ...

Dr. Soon-Shiong is hopeful the Saudi Arabian FDA's approval of his cancer therapy drug, Anktiva, will lead to widespread ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...